MMF 500 mg BD is UNDERDOSED for Autoimmune Hepatitis
The dose of mycophenolate mofetil (MMF) 500 mg twice daily (1,000 mg/day total) is insufficient for treating autoimmune hepatitis and should be increased to the recommended therapeutic dose of 1,500-2,000 mg/day (750-1,000 mg twice daily). 1
Correct Dosing Protocol
According to the 2025 EASL guidelines, the evidence-based dosing schedule for MMF in autoimmune hepatitis is:
- Initial dose: Start at 1,000 mg/day (500 mg BD) for the first 2 weeks
- Target therapeutic dose: Increase to 1,500-2,000 mg/day at week 2 (750-1,000 mg BD)
- Maintenance: Continue at 1,500-2,000 mg/day long-term 1
The current prescription of 500 mg BD represents only the initial starting dose and falls short of the therapeutic target by 50-75%.
Combination Therapy Required
MMF should not be used as monotherapy. The standard approach is:
- Prednisolone: 0.5 mg/kg/day (up to 1 mg/kg/day in severe cases), started simultaneously with MMF
- MMF: Initiated at the same time as corticosteroids (unlike azathioprine which starts 2 weeks later)
- Prednisolone is gradually tapered over 1-3 months to 5-10 mg/day as transaminases improve 1, 2
Monitoring Schedule
For MMF-treated patients, the monitoring is more straightforward than azathioprine due to lower toxicity risk:
Initial phase:
- Week 4: ALT, IgG, and safety biomarkers to evaluate for non-response (MMF toxicity is rare)
- Weeks 12 and 24: ALT and IgG to assess complete biochemical response (CBR)
Maintenance phase:
- Every 2-3 months until CBR achieved at 6 and 12 months
- Once CBR attained: Every 3-6 months to confirm sustained response
- Thyroid function: Every 6-12 months 1
Critical Safety Considerations
Pregnancy prevention is mandatory:
- Negative pregnancy test before starting
- Two forms of contraception required during treatment and for at least 12 weeks after discontinuation
- This applies to both females and males on MMF 1
Advantages over azathioprine:
- Much better tolerated with discontinuation rates of only 0-8% vs 15-36.5% for azathioprine
- No need for TPMT testing
- Rare toxicity makes monitoring simpler 1
Evidence Supporting Higher Doses
Recent meta-analyses demonstrate that MMF at proper dosing (1,500-2,000 mg/day) achieves:
- Superior complete biochemical remission rates compared to azathioprine (OR 2.56 short-term, OR 5.51 long-term)
- Significantly fewer serious adverse events (OR 0.15)
- Response rates of 62-92% in second-line use 1, 3
The FDA label for transplant indications confirms that while 2 g/day is effective, doses below this threshold may compromise efficacy 4.
Clinical Pitfall
The most common error is maintaining patients on the initial 1,000 mg/day dose without escalating to the therapeutic target of 1,500-2,000 mg/day at week 2. This underdosing likely explains treatment failures attributed to MMF in older literature 1.